A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy
Status:
Completed
Trial end date:
2019-10-02
Target enrollment:
Participant gender:
Summary
Repeated joint bleeding leads to hemophilic arthropathy (HA), which manifests with chronic
synovitis, cartilage damage and bony destruction. Currently available treatments of HA,
including analgesics, NSAIDs, and hyaluronic acid, are predominantly directed toward the
symptomatic relief of pain and inflammation, with no or little effect on joint cartilage
degeneration. AC201CR, a control released formulation of AC-201, demonstrates
anti-inflammatory effects by reducing NLRP3 inflammasome assembly. AC-201 is also unique in
that it influences both the anabolism and catabolism of chondrocytes in vitro and has shown
cartilage-sparing properties in animal studies. The study is designed to evaluate the joint
structure-modifying and symptom-relieving effects, safety, and tolerability of AC-201CR in
subjects with HA.